Thursday, May 23, 2013
Theravance to Present at Investor Conferences in June 2013
Monday, May 13, 2013
Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement
Friday, May 10, 2013
BREO™ ELLIPTA™ Gains US Approval for the Treatment of COPD
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
We partner with pharmaceutical companies to accelerate development and commercialization of our product candidates.
Every day at Theravance, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance discovers, develops and brings important medicines to patients by: